Abstract

BackgroundPulmonary endothelial cells’ (ECs) injury and apoptotic death are necessary and sufficient for the pathogenesis of the acute respiratory distress syndrome (ARDS), regardless of epithelial damage. Interaction of dysfunctional ECs with circulatory extracellular vesicles (EVs) holds therapeutic promise in ARDS. However, the presence in the blood of long-term ARDS survivors of EVs with a distinct phenotype compared to the EVs of non-surviving patients is not reported. With a multidisciplinary translational approach, we studied EVs from the blood of 33 patients with moderate-to-severe ARDS.ResultsThe EVs were isolated from the blood of ARDS and control subjects. Immunoblotting and magnetic beads immunoisolation complemented by standardized flow cytometry and nanoparticles tracking analyses identified in the ARDS patients a subset of EVs with mesenchymal stem cell (MSC) origin (CD73+CD105+Cd34−CD45−). These EVs have 4.7-fold greater counts compared to controls and comprise the transforming growth factor-beta receptor I (TβRI)/Alk5 and the Runx1 transcription factor. Time course analyses showed that the expression pattern of two Runx1 isoforms is critical for ARDS outcome: the p52 isoform shows a continuous expression, while the p66 is short-lived. A high ratio Runx1p66/p52 provided a survival advantage, regardless of age, sex, disease severity or length of stay in the intensive care unit. Moreover, the Runx1p66 isoform is transiently expressed by cultured human bone marrow-derived MSCs, it is released in the EVs recoverable from the conditioned media and stimulates the proliferation of lipopolysaccharide (LPS)-treated ECs. The findings are consistent with a causal effect of Runx1p66 expression on EC proliferation. Furthermore, morphological and functional assays showed that the EVs bearing the Runx1p66 enhanced junctional integrity of LPS-injured ECs and decreased lung histological severity in the LPS-treated mice.ConclusionsThe expression pattern of Runx1 isoforms might be a reliable circulatory biomarker of ARDS activity and a novel determinant of the molecular mechanism for lung vascular/tissue repair and recovery after severe injury.

Highlights

  • Pulmonary endothelial cells’ (ECs) injury and apoptotic death are necessary and sufficient for the pathogenesis of the acute respiratory distress syndrome (ARDS), regardless of epithelial damage

  • Human ARDS lung tissue is deficient of ITSN and shows limited EC proliferation As chronic deficiency of ITSN in a murine model of acute lung injury (ALI)/ARDS triggers a repair process characterized by EC proliferation and vascular remodeling [12], we investigated whether ITSN deficiency is a feature of ARDS human lung tissue

  • For biochemical evaluation of ITSN expression, total protein was extracted from frozen human non-disease controls (ND-Ctrl) lung (62 years old male, myocardial infarction) and ARDS tissue (36 years old male, pneumonia), extracellular vesicles (EVs) imaging EVs were labeled with biotin/neutrAvidin–Alexa Fluor 594 or double labeled with Alk5 rabbit Ab/anti-rabbit IgG Alexa Fluor 488 and biotin/neutrAvidin–Alexa Fluor 594 reporters [15]

Read more

Summary

Introduction

Pulmonary endothelial cells’ (ECs) injury and apoptotic death are necessary and sufficient for the pathogenesis of the acute respiratory distress syndrome (ARDS), regardless of epithelial damage. Growing evidence suggests that intercellular communication of injured ECs with the EVs released in vitro by the cultured bone marrow-derived MSCs ­(EVMSC) hold significant therapeutic promise for ARDS [6]. EVs are released from a variety of cells as byproducts of cell growth, apoptosis and in response to physiologic and pathophysiologic stimuli [7]. These EVs, known as microparticles, microvesicles, microsomes, lipid vesicles and exosomes encapsulate small portions of the subjacent cytosol, creating a heterogeneous population of phospholipid-walled vesicles [7, 8]. The number of circulating MSCs in peripheral blood is low, but injury and inflammatory states increase it; growing evidence indicates that MSCs migrate from their specific niches (i.e., bone marrow, adipose tissue, umbilical cord), transit through the blood to the injured tissue and promote the repair process [7, 9,10,11]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call